Hyperactivity and behavioural seizures in rodents following treatment with dopamine D1 receptor agonists A-86929 and ABT-431

European Journal of Pharmacology

Volumn 317, Issue 2-3, 1996, Pages 183-190

  Shiosaki, Kazumi ^a   Asin, Karen E ^a   Britton, Donald R ^a   Giardina, William J ^a   Bednarz, Lisa ^a   Mahan, Laura ^a   Mikusa, Joe ^a   Nikkel, Arthur ^a   Wismer, Carol ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

A 86929; AB 431; Dopamine D1 receptor; Hyperactivity; Seizure; Tolerance

Indexed keywords

4,5,5A,6,7,11B HEXAHYDRO 9,10 DIHYDROXY 2 PROPYL 3 THIA 5 AZACYCLOPENT 1 ENA[C]PHENANTHRENE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADROGOLIDE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; OXIDOPAMINE; PRODRUG; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

AGE; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; EXCITABILITY; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; SEIZURE; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; ANIMAL BEHAVIOR; CHEMICAL SYMPATHECTOMY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG POTENTIATION; MOTOR ACTIVITY; PSYCHOLOGICAL ASPECT; SPRAGUE DAWLEY RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOTOR ACTIVITY; OXIDOPAMINE; PRODRUGS; PYRIDINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; SEIZURES; SYMPATHECTOMY, CHEMICAL; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 0030593890     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00718-2     Document Type: Article

References (31)

1. Al-Tajir, G., C. Chander, B. Starr and M. Starr, 1990a, Opposite effects of stimulation of D1 and D2 dopamine receptors on the expression of motor seizures in mouse and rat, Neuropharmacology 29, 657.
2. Al-Tajir, G., M. Starr and B. Starr, 1990b, Proconvulsant effect of SKF 38393 mediated by nigral D1 receptors, Eur. J. Pharmacol 182, 245.
3. Andersen, P.H., E.B. Nielsen, J. Scheel-Kruger, J.A. Jansen and R. Hohlweg, 1987, Thienopyridine derivatives identified as the first selective, full efficacy, dopamine D1 receptor agonists, Eur. J. Pharmacol. 137, 291.
4. Arnt, J., 1985, Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats, Eur. J. Pharmacol. 113, 79.
5. Asin, K. and D. Wirtshafter, 1993, Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression, Eur. J. Pharmacol. 235, 167.
6. Barone, P., S.A. Parashos, V. Palma, C. Marin, G. Campanella and T. Chase, 1990, Dopamine D1 receptor modulation of pilocarpine-induced convulsions, Neuroscience 34, 209.
7. Braun, A. and T. Chase, 1988, Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists, Eur. J. Pharmacol. 147, 441.
8. Britton, D.R., K.E. Asin, L. Yahiro, P. Curzon, L. Bednarz and J. Williams, 1991, D1 dopamine receptor agonists induce forelimb clonus [abstract], Soc. Neurosci. 17, 638.
9. Burke, K., C.J. Chandler, B.S. Starr and M.S. Starr, 1990, Seizure promotion and protection by D-1 and D-2 dopaminergic drugs in the mouse, Pharmacol. Biochem. Behav. 36, 729.
10. Eilam, D., H. Talangbayan, G. Canaran and H. Szechtman, 1992, Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors, Psychopharmacology 106, 447.
11. Hodges, J.L., D. Krech and R. Crutchfield, 1975, Statlab: An Empirical Introduction to Statistics (McGraw-Hill, New York, NY) p. 185.
12. Jackson, D. and A. Westlind-Danielsson, 1994, Dopamine receptors: Molecular biology, biochemistry and behavioural aspects, Pharmacol. Ther. 64, 291.
13. Jenner, P., S. Rose, M. Nomoto and C. Marsden, 1986, MPTP-induced parkinsonism in the common marmoset: Behavioral and biochemical effects, Adv. Neurol. 45, 183.
14. Mattingly, B., J. Rowlett and G. Lovell, 1993, Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine, Psychopharmacology 110, 320.
15. Meyer, M. and J. Shults, 1993, Dopamine D1 receptor family agonists, SK&F38393, SK&F77434, and SK&F82958, differentially affect locomotor activities in rats, Pharmacol. Biochem. Behav. 46, 269.
16. Michaelides, M.R., Y. Hong, S.J. DiDomenico, K.E. Asin, D.R. Britton, C.W. Lin, M. Williams and K. Shiosaki, 1995, (5aR,11bS)-4,5,5a,6,7,11b-Hexahydro-2-propyl-3-thia-5-azacyclopent-1-ena[c]phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration, and characterization of its diacetyl prodrug (ABT-431), J. Med. Chem. 38, 3445.
17. Molloy, A. and J. Waddington, 1985, The enantiomers of SK&F 83566, a new selective D-1 dopamine antagonist, stereospecifically block stereotyped behaviour induced by apomorphine and by the selective D-2 agonist RU 24213, Eur. J. Pharmacol. 116, 183.
18. Molloy, A., K. O'Boyle, M. Pugh and J. Waddington, 1986, Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists, Pharmacol. Biochem. Behav. 25, 249.
19. Murray, A.M. and J.L. Waddington, 1989, The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction, Eur. J. Pharmacol. 160, 377.
20. Neisewander, J., I. Lucki and P. McGonigle, 1991, Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats, J. Pharmacol. Exp. Ther. 257, 850.
21. Ogren, S. and B. Pakh, 1993, Effects of dopamine D1 and D2 receptor agonists and antagonists on seizures induced by chemoconvulsants in mice, Pharmacol. Toxicol. 72, 213.
22. Post, R., 1980, Intermittent versus continuous stimulation: Effect of time interval on the development of sensitization or tolerance., Life Sci. 26, 1275.
23. Pugh, M., M. O'Boyles, A. Molloy and J. Waddington, 1985, Effects of the putative D-1 antagonist SCH 23390 on stereotyped behavior induced by the D-2 agonist Ru 24213, Psychopharmacology 87, 308.
24. Rao, P.A., P.B. Molinoff and J.N. Joyce, 1991, Ontogeny of dopamine D1 and D2 receptor subtypes in rat basal ganglia: a quantitative autoradiographic study, Brain Res. Dev. Brain Res. 60, 161.
25. Robertson, G. and H. Robertson, 1986, Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats, Brain Res. 384, 387.
26. Shiosaki, K., P. Jenner, K. Asin, D. Britton, C. Lin, M. Michaelides, L. Smith, B. Bianchi, S. DiDomenico, L. Hodges, Y. Hong, L. Mahan, J. Mikusa, T. Miller, A. Nikkel, M. Stashko, D. Witte and M. Williams, 1996, ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: In Vitro characterization and effects in animal models of parkinson's disease, J. Pharmacol. Exp. Ther. 276, 150.
27. Starr, M.S., 1996, The role of dopamine in epilepsy, Synapse 22, 159.
28. Tallarida, R.J. and R.B. Murray, 1987, Manual of pharmacological calculations with computer programs (Springer, New York, NY) p. 153.
29. Turski, W., E. Cavalheiro, C. Ikonomidou, Z. Bortolotto, T. Klockgether and L. Turski, 1990, Dopamine control of seizure propagation: intranigral dopamine-D1 agonist SKF-38393 enhances susceptibility to seizures, Synapse 5, 113.
30. White, F., H. Xiu-Ti and R. Brooderson, 1990, Repeated stimulation of dopamine D1 receptors enhances the effects of dopamine receptor agonists, Eur. J. Pharmacol. 191, 497.
31. Winkler, J. and B. Weiss, 1989, Effect of continuous exposure to selective D1 and D2 dopaminergic agonists on rotational behavior in supersensitive mice, J. Pharmacol. Exp. Ther. 249, 507.